TNFSF11 and Marchiafava-Bignami disease: The two approved pharmacological options for the treatment of MBD, bisphosphonates or denosumab (a monoclonal antibody inhibiting RANKL) [41], are both anti-resorptives and do little to drive the repair of existing bone lesions (Table 2).